TITLE

Hepatic haemangiomas: possible association with female sex hormones

AUTHOR(S)
Glinkova, V.; Shevah, O.; Boaz, M.; Levine, A.; Shirin, H.
PUB. DATE
September 2004
SOURCE
Gut;Sep2004, Vol. 53 Issue 9, p1352
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background and aims: The association of hepatic haemangiomas with female sex hormones is not entirely clear. We prospectively evaluated the impact of female sex hormones on the natural history of liver haemangiomas. Methods: We followed 94 women with 181 haemangiomas diagnosed by ultrasound for a period of -17 years (mean 7.3 (5.5) years). The location, number, size, and ultrasonographic pattern of the lesions were evaluated. Patients were also evaluated by questionnaire for gynaecological and reproductive history. We compared the change in number and size of haemangiomas in patients who received or did not receive exogenous hormonal treatment. = 0.015) while age at menopause was positively correlated with the number of haemangiomas detected at first ultrasound (r = 0.542, p>0.0001). During follow up, no change in the ultrasonographic pattern or number of haemangiomas was observed. An increase in the size of the lesions was demonstrated in 5/22 (22.7%) hormone therapy exposed patients compared with 7/72 (9.7%) controls. Three variables (ultrasonographic pattern, number of haemangiomas, and hormone therapy) predicted whether or not a given haemangioma would increase in size. A hypoechoic pattern increased the risk of progression while a hyperechoic pattern decreases that risk (p = 0.003). The number of haemangiomas was inversely associated with the likelihood of progression (p = 0.006) and hormone therapy increased the risk of haemangioma enlargement (p = 0.05). Conclusions: Hepatic haemangiomas seem to be influenced by both endogenous and exogenous female sex hormones although significant enlargement occurs only in a minority of patients. Consequently, routine liver ultrasound follow up in women with hepatic haemangiomas receiving hormone therapy appears appropriate.
ACCESSION #
14434525

 

Related Articles

  • Unraveling the Myths of Androgens: Introduction. Fitzpatrick, Lorraine A. // Journal of Family Practice;May2004 Supplement, Vol. 53, p2 

    One of the more puzzling issues in the treatment of postmenopausal women is how and when to prescribe androgen therapy. Many myths surround the use of androgen therapy. This article focuses on the supplement to the periodical “The Journal of Family Practice,” which is a condensed...

  • Estrogen Replacement Therapy Among Postmenopausal Women and Its Effects on Signs and Symptoms of Temporomandibular Disorders. Nekora-Azak, Aysen; Evlioglu, Gulumser; Ceyhan, Arzu; Keskin, Haluk; Berkman, Sinan; Issever, Halim // CRANIO: The Journal of Craniomandibular & Sleep Practice;Jul2008, Vol. 26 Issue 3, p211 

    The prevalence of temporomandibular disorders (TMD) is about two to five times higher in females than in males. Data for the higher prevalence of TMD in women and prevalence rates peak during the reproductive years and decrease after menopause. This indicated that female sex hormones may play a...

  • When HT makes sense. JVTR // Prevention;Feb2005, Vol. 57 Issue 2, p48 

    Discusses hormone therapy and how starting therapy prior to menopause may benefit the heart. Description of the Kronos Early Estrogen Prevention Study; What the study will investigate.

  • Estrogen Redux. Gorman, Christine // Time;3/15/2004, Vol. 163 Issue 11, p93 

    Discusses the decision of the National Institutes of Health (NIH) to halt a major study of the health effects of long-term estrogen use. Health risks associated with the combination of estrogen and progestin; How supplements of estrogen can increase a women's risk of breast cancer; Use of...

  • Hormone Replacement Therapy. Klotter, Jule // Townsend Letter;Nov2006, Issue 280, p37 

    The article focuses on a study, which focuses on estrogen or hormone replacement therapy (HRT) as a remedy for menopausal symptoms. According to some medical books and research, synthetic estrogen products increase the risk of breast cancer. Another trend in treating menopausal symptoms is the...

  • HRT does not prevent chronic disease after menopause. White, Caroline // BMJ: British Medical Journal (International Edition);4/17/2004, Vol. 328 Issue 7445, p912 

    Reports that hormone replacement therapy should not be used to prevent chronic disease in women who have gone through menopause. Role of hormone replacement therapy in the short term relief of menopausal symptoms; Descriptions of studies on the use of hormone replacement therapy; Need for women...

  • Estrogen-Progestin Increases Breast Cancer Risk. Stephens, Mark B. // Journal of Family Practice;Apr2000, Vol. 49 Issue 4, p301 

    The article calculates the risks of having breast cancer involved in the addition of progestin to estrogen in hormone replacement therapy (HRT). It discusses the use of HRT and estrogen replacement therapy in women who are in their postmenopausal period. A study was conducted as a follow-up to...

  • Can a Woman Be Feminine Forever? Sommers, Nancy; Ridgeway, James // New Republic;3/19/66, Vol. 154 Issue 12, p15 

    Discusses the hormonal therapy developed by gynecologist Robert A. Wilson to combat the effects of menopause among women. Wilson's book "Feminine Forever," in which he argued that if women take a prescribed dose of sex hormones they will not disintegrate into crones; Claim by Wilson that...

  • A response to critics of long-term postmenopausal hormone therapy. Speroff, Leon // Contemporary OB/GYN;Jul2002, Vol. 47 Issue 7, p98 

    Presents a response to critics of long-term postmenopausal hormone therapy. Arguments on which use of postmenopausal hormone therapy to treat menopausal symptoms are based; Basis for the argument against estrogen; Indication of case-control and cohort studies regarding estrogen.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics